GCC Breast Cancer Nursing Guide

◉Breast Anatomy Overview

Glandular tissue: 15–20 lobes arranged radially, drained by lactiferous ducts to nipple
Cooper's ligaments: suspensory ligaments — skin dimpling when involved by tumour
Tail of Spence: axillary extension — common site for palpable nodes
Blood supply: internal mammary artery, lateral thoracic artery
Lymphatic drainage: axillary (75%), internal mammary, supraclavicular chains
Axillary levels: Level I (lateral to pectoralis minor), II (behind), III (medial/apical)

!Clinical Presentation

Lump: painless, hard, irregular, fixed — most common presentation
Skin changes: dimpling, peau d'orange (lymphatic oedema), erythema
Nipple discharge: bloodstained, unilateral, from single duct — refer urgently
Nipple retraction/inversion: new onset — suspicious
Axillary lymphadenopathy: firm, matted, non-tender nodes
Paget's disease: eczematoid nipple change, unilateral — underlying DCIS/invasive ca
Inflammatory BC: rapid swelling, warmth, redness — entire breast involved; NO palpable lump; T4d — emergency referral

■Triple Assessment

1. Clinical Examination

Systematic inspection: arms raised, leaning forward
Palpation in supine position, all quadrants + axilla
Document: size, consistency, mobility, skin fixation
Check contralateral breast and regional nodes

2. Imaging

Mammography: first-line >35 yrs; bilateral; MLO + CC views
Ultrasound: <35 yrs or dense breasts; cyst vs solid; guides biopsy
MRI: lobular ca, multifocal disease, post-augmentation, BRCA carriers, response assessment
Reporting: BIRADS 0–6 classification

3. Pathological Biopsy

Core needle biopsy (CNB): preferred — histology + receptor status
FNA: cytology only; operator dependent
Vacuum-assisted biopsy: microcalcifications
Report: histological type, grade (1–3), ER/PR/HER2, Ki-67

◆TNM Staging (AJCC 8th Ed)

Stage	Description	5-yr Survival
I	T≤2cm, N0, M0 (IA) / micrometastasis (IB)	~99%
IIA/B	T0-2 N1 or T2-3 N0-1	~85–93%
IIIA/B/C	T3-4 or N2-3, locally advanced	~70–86%
IV	Any T, Any N, M1 (distant metastases)	~28%

GCC note: Younger women at diagnosis means pathological staging post-neoadjuvant therapy (ypTNM) increasingly used — affects prognosis discussions.

■Molecular Subtypes

Subtype	Receptors	Treatment Implication
Luminal A	ER+/PR+, HER2−, Ki67 low	Endocrine therapy; chemo often not needed
Luminal B	ER+, HER2− high Ki67 or HER2+	Endocrine + consider chemotherapy
HER2-enriched	ER−/PR−, HER2+	Anti-HER2 therapy + chemotherapy
Triple Neg	ER−/PR−/HER2−	Chemotherapy ± immunotherapy (PD-L1); PARP if BRCA+

■BRCA1/2 Awareness in GCC

BRCA mutations confer 65–80% lifetime breast cancer risk (BRCA1) and 45–65% (BRCA2).

GCC-Specific Founder Mutations

Arab populations: several BRCA1/2 variants with higher prevalence in Gulf region
Ashkenazi Jewish communities (present in Gulf): BRCA1 185delAG, 5382insC; BRCA2 6174delT — 3-mutation panel sufficient
Higher triple-negative rates in BRCA1 carriers — relevant to GCC Arab women

Nursing Role in Genetic Counselling

Refer to genetic counselling before testing — informed consent essential
Cultural sensitivity: family disclosure obligations vary — privacy vs duty to warn debate
Implications for siblings and daughters — discuss contralateral prophylactic mastectomy
BRCA+ men: elevated prostate and pancreatic cancer risk

■Reconstruction & Lymphoedema Risk

Breast Reconstruction Overview

Type	Details
Immediate	Same operation as mastectomy; better cosmesis; may delay RT
Delayed	After adjuvant treatment completed; safer if RT planned
Implant-based	Tissue expander then permanent implant; 2-stage; capsular contracture risk
TRAM flap	Transverse rectus abdominis myocutaneous; autologous; abdominal weakness risk
DIEP flap	Deep inferior epigastric perforator; preferred autologous; muscle-sparing
LD flap	Latissimus dorsi; smaller volume; often combined with implant

Lymphoedema Risk Factors

Axillary lymph node dissection (ALND) vs sentinel node biopsy (SLNB)
Radiotherapy to axilla/supraclavicular nodes
Obesity (BMI >30), infection, trauma to arm, air travel (prolonged)
Cumulative risk: up to 40% after ALND + RT

■Surgical Options: WLE vs Mastectomy

Procedure	Indication	Key Points
WLE / Lumpectomy	T1-2, unifocal, adequate breast size, patient choice	Requires post-op whole breast RT; equivalent survival to mastectomy; clear margins essential
Simple Mastectomy	DCIS, prophylactic, patient choice	Removes breast tissue + nipple; no axillary dissection
Modified Radical Mastectomy	Invasive cancer requiring mastectomy + ALND	Removes breast + axillary nodes levels I-III; pectoral muscles preserved
Skin-sparing Mastectomy	When immediate reconstruction planned	Preserves skin envelope; better cosmetic result with reconstruction
Nipple-sparing Mastectomy	Prophylactic or selected invasive cases, nipple not involved	Best cosmetic outcome; frozen section of nipple base intraoperatively

■Sentinel Lymph Node Biopsy (SLNB)

Technique

Blue dye (Patent Blue V / Methylene Blue): injected peri-areolar — stains lymphatics blue
Radiotracer (Tc-99m nanocolloid): injected day before or day of surgery; gamma probe guides surgeon
Dual technique preferred — higher detection rate (>95%)
SLNB negative → no further axillary surgery needed
SLNB positive (macrometastasis) → ALND or axillary RT decision per MDT

Nursing Precautions

Blue dye: warn patient of temporary blue urine/stool, skin staining (days–weeks)
Radiotracer: standard radiation precautions (low dose); avoid prolonged contact with pregnant staff
Allergic reaction to blue dye: anaphylaxis risk — have adrenaline available; pre-medicate if allergic history
Document sentinel node count and gamma counts intraoperatively

■Post-Op Drain Care

Closed suction drains (Redivac/Jackson-Pratt) placed in axilla and/or breast cavity
Record drain output every shift — document colour, consistency, volume
Empty and re-evacuate when >50% full to maintain suction
Remove criteria: output <30 mL/24 hours on two consecutive days
Seroma formation: most common complication post-mastectomy — aspirate if symptomatic
Ensure dressing intact; check for skin flap adherence
Patient education: how to empty drain at home, when to call (output suddenly increases, turbid fluid, fever)

Flap necrosis (reconstruction): Assess skin colour, capillary refill, turgor every 1–2 hours in first 24h. Report dusky/blue discolouration, skin blistering, or absent Doppler signal immediately.

!Arm Precautions After Axillary Dissection — Lymphoedema Prevention

AVOID on affected arm: Blood pressure measurement, venepuncture/blood draws, IV cannulation, injections, finger-prick glucose tests, tight jewellery/watch. These precautions are LIFELONG.

Avoid sunburn, cuts, insect bites on affected arm — infection triggers lymphoedema
Wear gloves for gardening, cooking (risk of burns/cuts)
Avoid extreme heat (saunas, hot tubs)
Heavy lifting: avoid >5 kg initially — build up gradually with physiotherapy guidance

Post-Op Exercises — Begin Day 1

Day 1: Pendulum exercises — gentle arm swings while seated, 10 reps ×3
Day 1–2: Hand and wrist movements, elbow flexion/extension
Day 2–3: Wall walking — fingers walk up wall to increase shoulder flexion daily
Day 4–7: Pulley exercises, clasping hands overhead
Goal: full shoulder ROM by 4–6 weeks
Refer to physiotherapy — structured programme
Drain in situ: limit shoulder abduction to 90° until drain removed

■Post-Operative Wound Assessment

Normal Healing

Wound edges approximated, no gaping
Minimal serous or serosanguinous drainage
Progressive wound closure, no erythema spreading
Sutures/staples intact until removal at 10–14 days

Complications to Report

Wound dehiscence — assess depth and extent
Haematoma — swelling, bruising, pain — may need surgical evacuation
Infection — erythema, warmth, purulent discharge, fever
Flap necrosis (reconstruction) — dusky skin, blistering

Nursing Documentation

TIMES framework: Tissue, Infection/Inflammation, Moisture, Edge, Surrounding skin
Wound photograph at each dressing change
Pain assessment (NRS 0–10) related to wound
Patient education: no soaking in water until wound healed

■Chemotherapy Regimens

Regimen	Drugs	Schedule	Key Nursing Points
AC-T	Doxorubicin + Cyclophosphamide → Paclitaxel or Docetaxel	AC ×4 cycles q3w, then T ×4 cycles q3w (or weekly Paclitaxel ×12)	Cardiac monitoring (doxorubicin); alopecia counselling; anti-emetic protocol essential
FEC-T	5-FU + Epirubicin + Cyclophosphamide → Docetaxel	FEC ×3 q3w, then Docetaxel ×3 q3w	Epirubicin — cardiotoxicity; mucositis risk with 5-FU; GCSF if dose-dense
Dose-Dense	AC-T q2w with GCSF support	q2w instead of q3w; GCSF day 2–14 or pegfilgrastim day 2	Monitor FBC closely; neutropenic sepsis protocol; fatigue management
Carboplatin	Added to taxane in TNBC or BRCA-mutated	AUC 5–6 q3w with taxane	Renal function monitoring (creatinine clearance); thrombocytopenia; nausea

Anti-emetic protocol: Anthracyclines (doxorubicin/epirubicin) = highly emetogenic — 5-HT3 antagonist + dexamethasone + NK1 antagonist (aprepitant) × 3 days. Taxanes = moderately emetogenic.

■HER2-Targeted Therapy

Trastuzumab (Herceptin)

Loading dose 8 mg/kg IV, then 6 mg/kg q3w (or 4 mg/kg → 2 mg/kg weekly)
Duration: 1 year (adjuvant setting)
Cardiac monitoring: ECHO or MUGA at baseline, every 3 months during treatment, and at end of treatment
Hold if LVEF drops >10% from baseline OR below 50%
Infusion reactions: first infusion — observe 6 hours; subsequent — 2 hours

Pertuzumab (Perjeta)

Combined with trastuzumab + docetaxel (TCHP regimen)
Main side effect: diarrhoea — prophylactic loperamide, fluid intake education
Loading dose 840 mg, then 420 mg q3w

T-DM1 / Trastuzumab Emtansine

For residual invasive disease after neoadjuvant HER2 therapy (KATHERINE trial)
Thrombocytopenia — monitor platelet count; neuropathy risk
Hepatotoxicity — LFTs before each cycle

Neratinib / Lapatinib

Oral tyrosine kinase inhibitors — extended adjuvant or metastatic
Severe diarrhoea — prophylactic loperamide titration protocol

■Endocrine Therapy

Tamoxifen (Pre-menopausal)

Dose: 20 mg oral daily × 5–10 years
DVT/PE risk: educate re: symptoms of VTE; avoid prolonged immobility; consider thromboprophylaxis perioperatively
Endometrial risk: report any postmenopausal bleeding immediately — annual gynaecological review
Hot flushes: venlafaxine 37.5 mg, clonidine; avoid SSRIs that inhibit CYP2D6 (reduce tamoxifen efficacy)
Cataracts: annual ophthalmology if symptomatic
Ovarian suppression (GnRH agonist) added in high-risk premenopausal women

Aromatase Inhibitors — Post-menopausal (or with OFS)

Anastrozole 1 mg / Letrozole 2.5 mg / Exemestane 25 mg — oral daily
Joint pain/arthralgia: most common side effect — exercise, NSAIDs, switch AI if severe
Bone density: DEXA scan at baseline and every 2 years; calcium 1200 mg/day + Vitamin D 800 IU
Bisphosphonate (zoledronic acid) if T-score <–2.0 or FRAX high risk
Vaginal dryness: non-hormonal moisturisers (Replens); topical oestrogen controversial in ER+ disease — MDT decision

■CDK4/6 Inhibitors

Used in ER+/HER2− metastatic breast cancer with endocrine therapy (fulvestrant or AI).

Palbociclib (Ibrance): 125 mg oral daily ×21 days, 7 days off
Ribociclib (Kisqali): 600 mg oral daily ×21 days, 7 days off
Abemaciclib (Verzenio): 150 mg twice daily (continuous); also adjuvant in high-risk node+
Neutropenia: most significant toxicity — FBC monthly for first 2 cycles, then each cycle
Grade 3–4 neutropenia: dose reduction or delay; GCSF generally not used
Ribociclib: QTc prolongation — ECG monitoring at baseline, day 14, day 28
Diarrhoea (abemaciclib): loperamide; dose reduction if >grade 2
Fatigue: sleep hygiene, activity pacing, energy conservation

■PARP Inhibitors & Immunotherapy

PARP Inhibitors (BRCA-mutated)

Olaparib (Lynparza): 300 mg twice daily; HER2− metastatic, or adjuvant high-risk early BRCA+
Talazoparib (Talzenna): 1 mg once daily; metastatic HER2− BRCA1/2+
Main toxicities: anaemia, nausea, fatigue — monitor FBC, renal and hepatic function
MDS/AML risk: rare but serious — report persistent cytopenias
Avoid concurrent GCSF if possible; dose reductions per protocol

Immunotherapy

Pembrolizumab (Keytruda): early TNBC (neoadjuvant + adjuvant) and metastatic PD-L1+
Immune-related adverse events (irAEs): thyroiditis, colitis, pneumonitis, hepatitis, dermatitis
Nursing: educate on irAE symptoms; TFTs, LFTs, glucose monitoring; hold if grade 2+; steroids for grade 3–4
No live vaccines during treatment

■Radiotherapy Indications & Schedules

Type	Schedule	Indication
Whole Breast RT (WBRT) — Hypofractionated	40 Gy / 15 fractions (3 weeks)	Post WLE — standard preferred
WBRT — Conventional	50 Gy / 25 fractions (5 weeks)	Selected cases, young patients, larger fields
Tumour Bed Boost	10–16 Gy / 4–8 fractions	Additional dose to excision site, especially <50 yrs or close margins
Post-Mastectomy RT (PMRT)	40–50 Gy / 15–25 fractions	T3/T4, ≥4 positive nodes, or 1–3 nodes per MDT
Nodal RT	Added to breast/chest wall field	Supraclavicular ± internal mammary nodes if high risk
Partial Breast Irradiation	38.5 Gy / 10 fractions	Selected low-risk T1 N0 post-WLE

■Skin Care During Radiotherapy

Grading of Skin Reaction (RTOG)

Grade 1 Faint erythema, dry desquamation — emollient moisturiser (aqueous cream, Radicare gel)
Grade 2 Tender erythema, patchy moist desquamation — Mepilex/Mepitel dressings, stop if in field
Grade 3 Confluent moist desquamation outside skin folds — consider treatment break; silver dressings; pain management
Grade 4 Ulceration, haemorrhage, necrosis — rare; halt RT; wound care team involvement

Daily Skin Care Instructions

Wash treated area gently with lukewarm water and mild soap; pat dry
Apply prescribed moisturiser 2–3× daily (not 1 hour before RT)
No deodorant/antiperspirant if axilla in field (aluminium-containing)
Avoid sun exposure to treated area (SPF 50 once healed; lifelong)
Loose-fitting cotton clothing; no underwired bra if skin reaction present
No swimming (chlorine) until skin healed; no shaving in treatment field

!Radiation-Induced Fatigue

Most common side effect — affects up to 80% of patients
Peaks in week 3–5 of treatment and may persist for months
Assessment: FACIT-Fatigue Scale or numeric rating 0–10 at each visit
Management: moderate aerobic exercise (evidence-based, 30 min ×5/week if tolerated)
Energy conservation: prioritise activities, rest periods, sleep hygiene
Rule out contributing factors: anaemia (check FBC), hypothyroidism, depression, poor nutrition
Psychological support: normalise the symptom; cognitive behavioural therapy for cancer-related fatigue
Nutritional support: adequate protein and caloric intake throughout RT

■Radiation Pneumonitis

Occurs 4–12 weeks post-RT. Risk higher with left-sided tumours, larger field, concurrent chemotherapy, and prior lung disease.

Signs & Symptoms

Dry, non-productive cough; dyspnoea on exertion progressing to rest
Low-grade fever; pleuritic chest pain
CXR/CT: ground-glass opacification conforming to radiation field

Management

Mild: observation, NSAIDs, cough suppressants
Moderate–Severe: prednisolone 1 mg/kg/day, slow taper over 4–6 weeks
Antibiotics only if secondary infection suspected
Refer pulmonology if no improvement with steroids

■DIBH — Deep Inspiration Breath Hold

Cardiac-sparing technique for left-sided breast cancer RT. Patient holds breath at deep inspiration, moving heart away from radiation field. Reduces mean cardiac dose by ~50%.

Nursing Preparation

Explain the procedure clearly in patient's language — Arabic interpreter if needed
Practice breathing technique in planning appointments (spirometry-guided or ABC device)
Patient must hold breath reproducibly for 20–25 seconds
Coaching: inhale to marked spirometer level, hold, breathe out normally
Elderly patients or those with respiratory compromise may need conventional free-breathing RT with cardiac blocking
Surface-guided RT (SGRT): cameras monitor chest surface — real-time gating

■Arm Lymphoedema Post-RT

Axillary radiotherapy + previous ALND = highest cumulative risk (>40%)
Onset: may be immediate (acute) or delayed months–years post-treatment
Symptoms: heaviness, tightness, aching, visible swelling of arm/hand
Assessment: measure circumference at 4 fixed points; compare to contralateral arm; >2 cm difference = significant
Refer to certified lymphoedema therapist (CLT) at first sign
Reinforce lifelong arm precautions (no BP/venepuncture on affected arm)
Compression garment fitting before long-haul flights
Infection (cellulitis) precipitates acute exacerbations — antibiotics promptly

■Survivorship Care Plan

Surveillance Schedule

Annual bilateral mammography (ipsilateral if WLE, contralateral always)
Years 1–3: clinical review every 3–6 months
Years 4–5: every 6–12 months
After year 5: annually
No routine CT/bone scan in asymptomatic survivors (unless metastatic concern)
MRI if dense breasts or BRCA carrier — annually

Bone Health (AI Users)

DEXA scan at baseline before starting AI
Repeat DEXA every 2 years on AI
Calcium 1200 mg/day + Vitamin D 800–1000 IU daily — all AI users
Bisphosphonate if T-score < –2.0 or fracture risk high (FRAX >20% 10-yr major)
Zoledronic acid 4 mg IV 6-monthly (also reduces recurrence in postmenopausal women)
Weight-bearing exercise recommendation

Cardiovascular Health

Anthracycline/trastuzumab recipients: annual cardiology review if LVEF affected
ECHO: baseline, 3-monthly on trastuzumab, at 1 year, then as indicated
Lifestyle: smoking cessation, weight management, regular exercise
BP and lipid monitoring for tamoxifen/AI users
Left-sided RT patients: cardiac risk counselling, ECG annually

■Complete Decongestive Therapy (CDT) — Lymphoedema

Gold standard for lymphoedema management — two phases: Intensive (Phase 1) and Maintenance (Phase 2).

Phase 1 — Intensive (2–4 weeks)

Manual Lymphatic Drainage (MLD): Vodder technique; gentle skin stretching movements; starts at lymph node groups above oedema to clear pathway; 45–60 min sessions, 5×/week
Multi-layer compression bandaging: foam padding + short-stretch bandages; worn 23 hours/day; removed for MLD only
Therapeutic exercises: active exercises with bandage on to activate muscle pump; diaphragmatic breathing
Meticulous skin care: pH-neutral moisturiser twice daily; antifungal between digits if maceration

Phase 2 — Maintenance (lifelong)

Compression garment (flat-knit >round-knit for significant lymphoedema): Class 2 (23–32 mmHg) minimum
Self-MLD taught to patient and caregiver
Twice daily moisturising; nail care; avoid trauma
Reassess garment fit every 6 months
Water exercises (hydrotherapy/swimming) — beneficial, compression off

■Psychosocial & Sexual Health

Body Image & Hair Loss

Chemotherapy-induced alopecia: begins 2–3 weeks after first cycle; most distressing side effect
Scalp cooling (cold cap) during infusion — reduces severity; less effective with anthracyclines
Wig/hairpiece fitting before alopecia — prescribe early; cultural considerations (hijab-wearing women)
Eyebrow pencilling, eyelash extensions — normalising appearance
Breast prosthesis fitting post-mastectomy: lightweight, water-resistant options
Refer to breast care nurse for reconstruction counselling and bra-fitter

Sexual Health & Vaginal Dryness

Aromatase inhibitors and tamoxifen cause vaginal atrophy, dryness, dyspareunia
ER-negative tumour: topical vaginal oestrogen safe — low systemic absorption
ER-positive tumour: avoid topical oestrogen; use non-hormonal vaginal moisturisers (Replens, Sylk) and lubricants
Ospemifene (SERM): discussed in consultation — avoid in ER+ disease generally
Pelvic floor physiotherapy referral for dyspareunia
Open, culturally sensitive discussions — privacy, partner involvement with consent

Cognitive Changes — "Chemo Brain"

Affects concentration, memory, processing speed during and after chemotherapy
Memory aids: lists, phone reminders, calendars
Cognitive rehabilitation referral if significant impairment
Reassure: usually improves 6–12 months post-treatment
Sleep optimisation — fatigue worsens cognition

■Epidemiology in the GCC Region

Most common cancer in GCC women — accounting for 25–35% of all female cancers across Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman.

Median age at diagnosis: ~46 years vs 61 years in Western populations — younger cohort
Higher proportion of premenopausal women at diagnosis (>50% in Gulf vs ~25% in UK)
Means fertility preservation, ovarian function, and hormonal issues are more prominent

Molecular Subtype Differences

Triple-negative subtype: higher prevalence in Arab and African populations (GCC: up to 25–30% vs 15% in Western)
Associated with younger age, higher grade, worse prognosis — reinforces importance of early detection
Luminal B more common than in Western populations
HER2 overexpression rates broadly comparable to international data
BRCA1/2 pathogenic variants more prevalent in some GCC communities

Presentation & Delays

Delayed presentation: culturally modesty-related barriers to breast self-examination
Fear of diagnosis — stigma associated with cancer in some communities
Limited awareness of breast cancer symptoms among general population
Higher proportion of Stage III–IV at presentation compared to Western centres
Male breast cancer: rare (<1%) but heavily stigmatised in GCC — even greater diagnostic delay

■Screening Programmes in GCC

Country	Age Recommendation	Programme Details
Saudi Arabia	40–69 years; 35+ if high risk	National Breast Cancer Awareness Month campaigns; mammography via MOH primary health centres; Mammography vans in remote regions
UAE	40–75 years; 35+ if high risk	UAE Cancer Registry; Pink Caravan initiative; mammography at government and private centres; annual
Qatar	40+ years	Hamad Medical Corporation programme; genetic testing integrated for family history
Kuwait / Bahrain / Oman	40–69 years; varies	Developing national programmes; private sector participation; awareness campaigns October annually

Nursing role: Actively promote screening uptake. Address modesty concerns — female radiographers and clinicians when possible; same-gender healthcare provider requests respected under Islamic healthcare ethics.

■Cultural & Religious Considerations

Islamic Ruling on Mastectomy & Reconstruction

Islamic jurisprudence (fiqh) permits surgery including mastectomy and reconstruction when medically necessary — preserving health (hifz al-nafs) is an Islamic obligation
Reconstruction is permitted to restore body image and psychological well-being
Tattooing (nipple reconstruction) is discussed — some scholars permit for medical reconstruction
Involve Islamic scholar/chaplain if family requests religious guidance

BRCA Testing: Family Disclosure Ethics

Strong family ties in GCC — duty to inform relatives vs right to privacy
Discuss cascade testing with genetic counsellor — responsibility without coercion
Some families prefer joint decision-making rather than individual model
Confidentiality: nurse must maintain individual patient's privacy first

Male Breast Cancer in GCC

Cultural stigma: "women's disease" — men often delay presentation by years
BRCA2 most common genetic cause in male breast cancer
Nurse advocacy: normalise discussion; use clinical language; involve male relatives/friends for support

■Ramadan & Chemotherapy

Many GCC patients will fast during Ramadan. Proactive MDT planning is required — do not wait for patient to raise it.

Dehydration risk: especially with taxanes, platinum-based regimens — pre-hydration schedules may need adjustment; IV fluids during fasting are generally permitted under Islamic exemption for medical necessity
Oral medication timing: rescheduling to non-fasting hours (pre-Fajr / post-Iftar) where pharmacologically appropriate — discuss with pharmacist
Immune function: fasting and disrupted sleep patterns may impact neutrophil recovery — closer FBC monitoring
Religious exemption: Islam exempts the ill from fasting (Quran 2:184–185); spiritual counsellor support for patients who feel conflicted
Chemotherapy appointment times: offer pre-Fajr (early morning) or evening post-Iftar slots where feasible
Assess: patient intent to fast → document → include in care plan

■Fertility Preservation & Arabic BSE Education

Fertility Preservation Before Chemotherapy

Critical in GCC given younger age at diagnosis and cultural importance of motherhood
Refer urgently to reproductive endocrinology before starting chemotherapy (ideally within 1–2 weeks of diagnosis)
Options: embryo cryopreservation (married women), oocyte cryopreservation, ovarian tissue cryopreservation
Islamic ruling: embryo freezing permitted for married couples; donor egg/surrogacy not permitted
GnRH agonist (goserelin) during chemotherapy: may protect ovarian function — discuss with oncologist
Post-chemotherapy: discuss pregnancy timing (generally wait 2 years), BRCA implications for offspring

Arabic Breast Self-Examination Education

Provide bilingual (Arabic/English) BSE instruction materials
Monthly BSE: best 7–10 days after menstruation (premenopausal); fixed date monthly (postmenopausal)
Method: visual inspection in mirror (arms raised, pressed on hips) + palpation lying down and standing
Cultural framing: BSE as caring for the body that is an amanah (trust from God)
Include female family members in education sessions where patient consents
Community nurses: outreach to mosques, women's groups, schools — normalise breast awareness